Literature DB >> 22451316

Toward a brain-computer interface for Alzheimer's disease patients by combining classical conditioning and brain state classification.

Giulia Liberati1, Josué Luiz Dalboni da Rocha, Linda van der Heiden, Antonino Raffone, Niels Birbaumer, Marta Olivetti Belardinelli, Ranganatha Sitaram.   

Abstract

Brain-computer interfaces (BCIs) provide alternative methods for communicating and acting on the world, since messages or commands are conveyed from the brain to an external device without using the normal output pathways of peripheral nerves and muscles. Alzheimer's disease (AD) patients in the most advanced stages, who have lost the ability to communicate verbally, could benefit from a BCI that may allow them to convey basic thoughts (e.g., "yes" and "no") and emotions. There is currently no report of such research, mostly because the cognitive deficits in AD patients pose serious limitations to the use of traditional BCIs, which are normally based on instrumental learning and require users to self-regulate their brain activation. Recent studies suggest that not only self-regulated brain signals, but also involuntary signals, for instance related to emotional states, may provide useful information about the user, opening up the path for so-called "affective BCIs". These interfaces do not necessarily require users to actively perform a cognitive task, and may therefore be used with patients who are cognitively challenged. In the present hypothesis paper, we propose a paradigm shift from instrumental learning to classical conditioning, with the aim of discriminating "yes" and "no" thoughts after associating them to positive and negative emotional stimuli respectively. This would represent a first step in the development of a BCI that could be used by AD patients, lending a new direction not only for communication, but also for rehabilitation and diagnosis.

Entities:  

Mesh:

Year:  2012        PMID: 22451316     DOI: 10.3233/JAD-2012-112129

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

1.  Informed Consent in Implantable BCI Research: Identifying Risks and Exploring Meaning.

Authors:  Eran Klein
Journal:  Sci Eng Ethics       Date:  2015-10-23       Impact factor: 3.525

Review 2.  Real-time fMRI neurofeedback: progress and challenges.

Authors:  J Sulzer; S Haller; F Scharnowski; N Weiskopf; N Birbaumer; M L Blefari; A B Bruehl; L G Cohen; R C DeCharms; R Gassert; R Goebel; U Herwig; S LaConte; D Linden; A Luft; E Seifritz; R Sitaram
Journal:  Neuroimage       Date:  2013-03-27       Impact factor: 6.556

Review 3.  Blending Electronics with the Human Body: A Pathway toward a Cybernetic Future.

Authors:  Mehdi Mehrali; Sara Bagherifard; Mohsen Akbari; Ashish Thakur; Bahram Mirani; Mohammad Mehrali; Masoud Hasany; Gorka Orive; Paramita Das; Jenny Emneus; Thomas L Andresen; Alireza Dolatshahi-Pirouz
Journal:  Adv Sci (Weinh)       Date:  2018-08-01       Impact factor: 16.806

4.  Detection of residual cognitive function through non-spontaneous eye movement in a patient with advanced frontotemporal dementia.

Authors:  Akira Midorikawa; Chihiro Itoi; Mitsuru Kawamura
Journal:  Front Neurosci       Date:  2014-10-24       Impact factor: 4.677

5.  Cognitive Improvement and Brain Changes after Real-Time Functional MRI Neurofeedback Training in Healthy Elderly and Prodromal Alzheimer's Disease.

Authors:  Christian Hohenfeld; Nils Nellessen; Imis Dogan; Hanna Kuhn; Christine Müller; Federica Papa; Simon Ketteler; Rainer Goebel; Armin Heinecke; N Jon Shah; Jörg B Schulz; Martina Reske; Kathrin Reetz
Journal:  Front Neurol       Date:  2017-08-09       Impact factor: 4.003

6.  Insula and inferior frontal triangularis activations distinguish between conditioned brain responses using emotional sounds for basic BCI communication.

Authors:  Linda van der Heiden; Giulia Liberati; Ranganatha Sitaram; Sunjung Kim; Piotr Jaśkowski; Antonino Raffone; Marta Olivetti Belardinelli; Niels Birbaumer; Ralf Veit
Journal:  Front Behav Neurosci       Date:  2014-07-21       Impact factor: 3.558

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.